Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce.

A new survey from Resume Now® reveals that while many workers aspire to change careers, financial fears and skill gaps are keeping them stuck in jobs they no longer find fulfilling. According to the ...